- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.02. | Dismay as FDA blocks Regenxbio's Hunter syndrome therapy | ||
| 10.02. | Lupin settles Myrbetriq patent spat with Astellas for $90m | ||
| 09.02. | Lilly strikes again, buying CAR-T firm Orna for $2.4bn | ||
| 09.02. | Data builds on Roche's dominance in primary progressive MS | ||
| 09.02. | Novartis breaks ground on San Diego biomedical R&D site | ||
| 09.02. | Lilly strikes $8.8bn-plus alliance with China's Innovent | ||
| 09.02. | Novo Nordisk rises as Hims & Hers backs down on oral GLP-1 | ||
| 06.02. | Leqembi starts to deliver for Eisai and Biogen | ||
| 06.02. | Bayer reveals data behind asundexian's stroke win | ||
| 06.02. | White House's TrumpRx platform has arrived | ||
| 05.02. | Hims & Hers copies Novo Nordisk's new Wegovy pill | ||
| 05.02. | Flagship's AI-focused Generate Biomedicines files IPO | ||
| 05.02. | Amgen baulks at FDA request to withdraw Tavneos | ||
| 05.02. | Grail multi-cancer test taps into Hims & Hers network | ||
| 05.02. | Abbott's wireless heart failure sensor cleared for NHS use | ||
| 05.02. | Eikon, Veradermics close IPOs, as Salspera joins queue | ||
| 04.02. | Lilly says 2026 looks good, as sales rocket in Q4 | ||
| 04.02. | GSK delivers in new CEO Miels' first financial update | ||
| 04.02. | Novo Nordisk slumps on tougher 2026 financial outlook | ||
| 04.02. | Patent losses hit Novartis hard, but CEO has a plan | ||
| 04.02. | Fears US drug pricing deal will weigh heavy on the NHS | ||
| 03.02. | GSK departs Wave's AATD programme | ||
| 03.02. | FDA knocks back AstraZeneca's self-injected lupus drug | ||
| 03.02. | UK will cover transport costs for children with cancer | ||
| 03.02. | Novo Nordisk's CagriSema tops Ozempic in diabetes trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.